TY - JOUR
T1 - COMT inhibition
T2 - A new treatment strategy for Parkinson's disease
AU - Kurth, Matthias C.
AU - Adler, Charles H.
PY - 1998
Y1 - 1998
N2 - During the initial stages of Parkinson's disease, treatment with levodopa plus a decarboxylase inhibitor (carbidopa or benserazide) provides adequate control of symptoms. However, as the disease progresses, the clinical response to treatment often begins to fluctuate, becoming increasingly correlated with fluctuations in plasma concentrations of levodopa-the 'wearing-off' phenomenon. Many strategies have attempted, with various degrees of success, to increase the availability of levodopa and its active metabolites, thus reducing these fluctuations in response. This review focuses on the role of the new catechol O-methyltransferase (COMT) inhibitors tolcapone and entacapone as adjuncts to levodopa therapy. These agents act effectively and safely to increase the amount of levodopa that is available to enter the brain by extending the half-life of levodopa, resulting in more stable levels in the plasma and prolonging 'on' time.
AB - During the initial stages of Parkinson's disease, treatment with levodopa plus a decarboxylase inhibitor (carbidopa or benserazide) provides adequate control of symptoms. However, as the disease progresses, the clinical response to treatment often begins to fluctuate, becoming increasingly correlated with fluctuations in plasma concentrations of levodopa-the 'wearing-off' phenomenon. Many strategies have attempted, with various degrees of success, to increase the availability of levodopa and its active metabolites, thus reducing these fluctuations in response. This review focuses on the role of the new catechol O-methyltransferase (COMT) inhibitors tolcapone and entacapone as adjuncts to levodopa therapy. These agents act effectively and safely to increase the amount of levodopa that is available to enter the brain by extending the half-life of levodopa, resulting in more stable levels in the plasma and prolonging 'on' time.
UR - http://www.scopus.com/inward/record.url?scp=0031923914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031923914&partnerID=8YFLogxK
U2 - 10.1212/wnl.50.5_suppl_5.s3
DO - 10.1212/wnl.50.5_suppl_5.s3
M3 - Article
C2 - 9591516
AN - SCOPUS:0031923914
SN - 0028-3878
VL - 50
SP - S3-S14
JO - Neurology
JF - Neurology
IS - 5 SUPPL. 5
ER -